June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Visual outcomes in uveitis with angiographic macular leakage treated with the fluocinolone acetonide implant or standard treatment
Thomas Albini; Debra Goldstein; David Callanan; Quan Dong Nguyen; Sunil Srivastava
Author Affiliations & Notes
  • Thomas Albini
    Ophthalmology, Bascom Palmer Eye Institute, Miami, FL
  • Debra Goldstein
    Ophthalmology, Northwestern Universty, Chicago, IL
  • David Callanan
    Ophthalmology, Texas Retina Associates, Dallas, TX
  • Quan Dong Nguyen
    Ophthalmology, Johns Hopkins University, Baltimore, MD
  • Sunil Srivastava
    Ophthalmology, Cleveland Clinic, Cleveland, OH
  • Footnotes
    Commercial Relationships Thomas Albini, Bausch and Lomb (C), Allergan (C), Genentech (F), Eleven Biotherapeutics (C); Debra Goldstein, Bausch and Lomb (C), Bausch and Lomb (R); David Callanan, Alcon (C), Alcon (R), Allergan (C), Allergan (R), Bausch & Lomb (C), Bausch & Lomb (R), Thrombogenics (R), Santen (C), Forsight (I), Regeneron (F); Quan Dong Nguyen, Genentech (F), Regeneron (F), Lux Biosciences (F), Abbott (F), GSK (F), Santen (F), Santen (C), Bausch and Lomb (C), Optos (F), Heidelberg Engineering (F); Sunil Srivastava, Bausch and Lomb (F), Bausch and Lomb (C), Novartis (F), Allergan (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5933. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Visual outcomes in uveitis with angiographic macular leakage treated with the fluocinolone acetonide implant or standard treatment
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Thomas Albini, Debra Goldstein, David Callanan, Quan Dong Nguyen, Sunil Srivastava; Visual outcomes in uveitis with angiographic macular leakage treated with the fluocinolone acetonide implant or standard treatment. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5933.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: Macular leakage associated with cystoid macular edema is a common cause of severe vision loss in patients with uveitis. This study examines the visual acuity outcomes of eyes treated with implant as compared to fellow eyes or those treated with standard of care.

Methods: Patients with macular leakage at baseline were identified from three prospective, randomized clinical trials examining the use of fluocinolone acetonide in the treatment of non-infectious posterior uveitis. Fluorescein angiograms were performed on each patient at regular time points. A centralized reading center analyzed and graded each angiogram. Visual outcomes were examined and analyzed at baseline and the two year time point. Three specific treatment groups were identified and analyzed - those eyes treated with the fluocinolone acetonide implant (IMP), fellow eyes (FEL) of patients with implants and eyes treated with standard of care systemic (SOC) medications.

Results: A total of 250 eyes treated with the IMP device had macular leakage identified at baseline. In comparision, 163 FEL eyes and 59 SOC eyes had baseline macular leakage. The mean baseline logMAR visual acuity was significantly worse in IMP and FEL eyes (.56 in both) vs SOC eyes (.39), (p<.01). IMP eyes had a significantly greater improvement of vision over 24 months (.56 to .41) in comparision to both SOC eyes (.39 to .40) and FEL eyes (.56 to .64), (p<.01). In eyes without evidence of macular leakage at baseline, all groups had some improvement of vision over 24 months: IMP (.41 to .33), FEL (.28 to .24) and SOC (.12 to .09). The amount of improvement was not statistically different between these groups.

Conclusions: In eyes with fluorescein evidence of macular leakage, fluocinolone acetonide device resulted in a statistically significant greater improvement in visual acuity over 24 months vs FEL eyes and SOC eyes. In eyes with macular leakage, the fluocinolone acetonide device may offer superior improvement of visual acuity over 2 years in comparison to eyes treated with standard of care therapy.

Keywords: 746 uveitis-clinical/animal model • 557 inflammation • 462 clinical (human) or epidemiologic studies: outcomes/complications  
© 2013, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept